{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:21Z","timestamp":1790767821603,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01746-6","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:46:38Z","timestamp":1776674798000},"page":"2965-2978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results"],"prefix":"10.1007","volume":"16","author":[{"given":"Michael","family":"Cecchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Kwiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu-Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Harakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika H.","family":"Noss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Orillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Tikhonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"12","key":"1746_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S Stander","year":"2021","unstructured":"Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"1746_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(25)00003-7","volume":"13","author":"GBD 2021 Asthma and Allergic Diseases Collaborators","year":"2025","unstructured":"GBD 2021 Asthma and Allergic Diseases Collaborators. Global, regional, and national burden of asthma and atopic dermatitis, 1990\u20132021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir Med. 2025;13(5):425\u201346.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1746_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1346-8138.2011.01295.x","volume":"39","author":"N Maksimovic","year":"2012","unstructured":"Maksimovic N, Jankovic S, Marinkovic J, Sekulovic LK, Zivkovic Z, Spiric VT. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39(1):42\u20137.","journal-title":"J Dermatol"},{"issue":"8","key":"1746_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","volume":"154","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903\u201312.","journal-title":"JAMA Dermatol"},{"issue":"21","key":"1746_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111898","volume":"22","author":"MA Galvan Morales","year":"2021","unstructured":"Galvan Morales MA, Montero-Vargas JM, Vizuet-de-Rueda JC, Teran LM. New insights into the role of PD-1 and its ligands in allergic disease. Int J Mol Sci. 2021;22(21):11898.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1746_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202551820","volume":"55","author":"H Mehta","year":"2025","unstructured":"Mehta H, Pellerin L, Rubio M, et al. Tissue-resident memory and follicular\/peripheral helper PD-1+ T cells infiltrate lesional skin in atopic dermatitis. Eur J Immunol. 2025;55(6):e51820.","journal-title":"Eur J Immunol"},{"issue":"suppl 1","key":"1746_CR7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ard.2025.05.977","volume":"84","author":"I Ling","year":"2025","unstructured":"Ling I, Marciniak S, Clarke S, et al. Safety, tolerability, and activity of JNJ-67484703 in participants with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase 1b study. Ann Rheum Dis. 2025;84(suppl 1):794\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"1746_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ard.2025.05.482","volume":"84","author":"BA Fisher","year":"2025","unstructured":"Fisher BA, van de Wiel J, Turner JD, et al. Pharmacodynamic activity of JNJ-67484703 in rheumatoid arthritis, ulcerative colitis and Sj\u00f6gren\u2019s disease (Paris): results of a phase II proof of biology trial. Ann Rheum Dis. 2025;84(suppl 1):389\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1746_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70006","volume":"13","author":"YJ Chen","year":"2024","unstructured":"Chen YJ, Chen Y, Chen P, Jia YQ, Wang H, Hong XP. Characteristics of PD-1+CD4+ T cells in peripheral blood and synovium of rheumatoid arthritis patients. Clin Transl Immunol. 2024;13(10):e70006.","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"1746_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-07008-3","volume":"15","author":"S Abe","year":"2025","unstructured":"Abe S, Tsuboi H, Aoki H, et al. T follicular helper 1 cells in blood potentially mirror salivary gland-infiltrating T cells in Sj\u00f6gren\u2019s disease. Sci Rep. 2025;15(1):23520.","journal-title":"Sci Rep"},{"issue":"11","key":"1746_CR11","volume":"17","author":"DM Khan","year":"2025","unstructured":"Khan DM, Kumar R, Sriharsha M, Mahavadi S, Kishore A. Immune checkpoint dysregulation in autoimmune disorders: a narrative review of therapeutic implications. Cureus. 2025;17(11):e97002.","journal-title":"Cureus"},{"key":"1746_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112663","volume":"139","author":"H Liu","year":"2024","unstructured":"Liu H, Wang G, Liu X, et al. Novel insights into immune checkpoints in psoriasis and atopic dermatitis: from expression and function to treatments. Int Immunopharmacol. 2024;139:112663.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1746_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1684\/ecn.2013.0333","volume":"24","author":"M Auriemma","year":"2013","unstructured":"Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. Eur Cytokine Netw. 2013;24(1):37\u201344.","journal-title":"Eur Cytokine Netw"},{"issue":"24","key":"1746_CR14","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1746_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","volume":"20","author":"LF Eichenfield","year":"2019","unstructured":"Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443\u201356.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1746_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40257-025-00917-z","volume":"26","author":"M Napolitano","year":"2025","unstructured":"Napolitano M, Esposito M, Fargnoli MC, et al. Infections in patients with atopic dermatitis and the influence of treatment. Am J Clin Dermatol. 2025;26(2):183\u201397.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01746-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:20Z","timestamp":1780584800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01746-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Cecchini is a medical dermatologist and was a principal investigator in this study. Bartlomiej Kwiek was a principal investigator in this study and reports serving as a clinical study investigator for AbbVie, Almirall, Amgen Inc, Arcutis Biotherapeutics, Aslan, Bristol Myers Squibb, Celdex Therapeutics, Celltrion, Dermira, Galderma, Glenmark, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron, and Samsung. Fang Liu-Walsh, Michael Scully, Jessica Harakal, Erika H. Noss, Ashley Orillion, He Li, Bin Gao, and Ilia Tikhonov are employees of Johnson & Johnson and own shares or stock options of Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the institutional review board at each study site (complete list is provided in Table\u00a0\n                      \n                      ). The study was conducted in accordance with International Council for Harmonisation Good Clinical Practice, the principles of the Declaration of Helsinki, and requirements of local ethics committees. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}